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Objectives. We sought to show that hirudin might interact
differently with streptokinase (SK) and tissue-type plasminogen
activator (t-PA), which could reduce the incidence of death or
reinfarction at 30 days.
Background. In a large-scale trial of patients with acute coro-
nary syndromes, hirudin provided modest benefit compared with
heparin. However, the interaction with thrombolytic agents was
not specifically assessed.
Methods. Patients with symptoms of acute myocardial infarc-
tion and electrocardiographic ST segment elevation were treated
with thrombolytic therapy and randomly assigned to receive
hirudin or heparin.
Results. A total of 2,274 patients received t-PA, and 1,015
received SK. Baseline characteristics were balanced by antithrom-
bin assignment. Among SK-treated patients, death or reinfarction
at 30 days occurred more often in those treated with adjunctive
heparin (14.4%) rather than hirudin (8.6%, odds ratio [OR] 1.78,
95% confidence interval [CI] 1.20 to 2.66, p 5 0.004). Among
t-PA–treated patients, the rates were 10.9% with heparin and
10.3% with hirudin (OR 1.06, 95% CI 0.81 to 1.38, p 5 0.68; for
treatment heterogeneity: chi-square 4.20, degrees of freedom [df]
1, p 5 0.04). After adjustment for baseline differences between
thrombolytic groups, the rates were 9.1% for SK with hirudin,
10.3% for t-PA with hirudin, 10.5% for t-PA with heparin and
14.9% for SK with heparin (for treatment heterogeneity: chi-
square 4.5, df 1, p 5 0.03), suggesting that the beneficial treat-
ment effect of hirudin was limited to the SK-treated patients.
Conclusions. Hirudin interacts favorably with SK but not t-PA,
highlighting the importance of thrombin activity after SK therapy
and the potential for simulating the effects of a more potent
fibrinolytic agent through direct antithrombin therapy.
(J Am Coll Cardiol 1998;31:1493–8)
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Since the results of the Global Utilization of Streptokinase and
Tissue Plasminogen Activator [tissue-type plasminogen activa-
tor] (t-PA) for Occluded Coronary Arteries (GUSTO-I) trial
were published in 1993 (1), accelerated t-PA combined with
intravenous heparin has become the thrombolytic regimen
used most often to treat myocardial infarction (MI) in the
United States. This regimen provided a 15% relative reduction
in 30-day mortality compared with streptokinase (SK) and
either intravenous or subcutaneous heparin (2). No other
combination of a thrombolytic agent and an antithrombin
agent has since yielded an incremental survival benefit as great.
The major limitations of heparin, the standard antithrom-
bin therapy, are that it works indirectly, requires antithrombin
III as a cofactor and is ineffective against clot-bound thrombin
(3). Newer antithrombotic agents, such as hirudin (the proto-
typic direct thrombin inhibitor), act against both free and
clot-bound thrombin and lack most of the qualities that can
interfere with the action of heparin. The advent of these drugs
raised the hope that their concomitant use would improve the
efficacy of SK (4–7). However, neither heparin nor any other
antithrombin agent has been shown, when combined with SK,
to improve 30-day survival (8,9).
SK remains the least expensive thrombolytic agent, and
enhancing its efficacy with adjuvant therapy would have signif-
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icant public health and economic effects. The primary hypoth-
esis of the current study was that hirudin might interact
differently with SK and t-PA, which could reduce the incidence
of death or reinfarction at 30 days for one of these agents. This
substudy was a prospective secondary analysis of the Global
Use of Strategies to Open Occluded Coronary Arteries in
Acute Coronary Syndromes (GUSTO-IIb) trial (10).
Methods
Patient population. The GUSTO-IIb trial enrolled 12,142
patients with acute coronary syndromes, of whom 3,457
(28.5%) received thrombolytic therapy, either at the discretion
of the attending physician or within a randomized substudy
(10,11). When patients were randomized to hirudin or heparin
treatment, they were stratified by the presence of ST segment
elevation $1 mm in at least two contiguous leads associated
with chest discomfort within the previous 12 h. Of the 3,457
patients who received thrombolytic agents, 3,052 were consid-
ered to meet the criteria for ST segment elevation and 405
were not. Of these 405 patients who did not have initial ST
elevation $1 mm, we included in our analysis those who had
ST segment elevation $0.5 mm who received thrombolytic
therapy within 6 h after enrollment. We excluded only 14
patients who received both SK and t-PA from analysis. The
resulting cohort used for all analyses therefore included 3,289
patients, of whom 3,041 were stratified in the ST segment
elevation group and 248 were not.
Patients were excluded from the GUSTO-IIb trial for active
bleeding, a history of stroke, contraindication to heparin, renal
insufficiency (serum creatinine concentration .2.0 mg/dl [177
mmol/liter]), systolic blood pressure .200 mm Hg or diastolic
blood pressure .110 mm Hg, warfarin use at enrollment or
childbearing potential. If a patient was enrolled and it was later
determined that the serum creatinine at enrollment had ex-
ceeded 2.0 mg/dl, the study drug was discontinued.
In patients with ST segment elevation, after they were
randomly assigned to hirudin or heparin therapy, the decision
to use thrombolytic therapy was made by the attending physi-
cian, as was the choice between an accelerated t-PA regimen or
SK. A subset of patients eligible for thrombolysis was enrolled
in the GUSTO-IIb direct angioplasty substudy (11), in which
patients were randomized to undergo coronary angioplasty or
receive accelerated t-PA as in the GUSTO-I trial (2).
The study medication (hirudin or heparin) was to be
infused for 3 to 5 days. The heparin doses were those used in
GUSTO-I (2): a 5,000-U intravenous bolus followed by an
infusion of 1,000 U/h, with no increase in infusion rate for
heavier patients. The hirudin dose was a bolus of 0.1 mg/kg
body weight followed by an infusion of 0.1 mg/kg per hour. The
activated partial thromboplastin time (aPTT) was measured
before administration of study drug; at 6, 12 and 24 h and at
least daily for the duration of the infusion. The study drug
infusion rate was adjusted by use of a standard nomogram to
maintain the aPTT between 60 and 85 s. Study drug infusion
rates could be decreased (but not increased) in response to the
measures at 6 and 12 h.
All patients were given chewable aspirin (160 mg) on
presentation, followed by up to 325 mg of oral aspirin daily.
The use of all other medications and interventions was at the
discretion of the attending physician.
End points. The primary end point was the composite
incidence of death or nonfatal reinfarction within 30 days of
enrollment. The 30-day rates of mortality, nonfatal reinfarc-
tion and a composite of death or reinfarction in the subgroup
of patients with ST segment elevation were prospectively
defined secondary end points of the GUSTO-IIb trial (10).
These end points also were assessed at 24 h because they would
reflect differences in outcomes between groups during infusion
of the study drug. In-hospital bleeding and selected 30-day
clinical outcomes were also assessed.
Severe or life-threatening bleeding was defined as intracranial
hemorrhage or bleeding that caused hemodynamic compro-
mise requiring intervention. Moderate bleeding was defined as
spontaneous gross hematuria, hematemesis or a decline in
hemoglobin .3 g/d if associated with observed blood loss or
.4 g/dl if no bleeding site was identified.
Statistical analysis. Statistical analyses included all ran-
domized patients who met the criteria for inclusion in our
substudy, according to the intention to treat principle. Com-
parisons of the treatment groups with regard to the primary
and discrete secondary end points were performed using the
conventional chi-square test. All p values are two-tailed; p ,
0.05 was considered statistically significant.
A multivariable logistic regression model was used to assess
the possibility of a specific thrombolytic–antithrombin interac-
tion after adjusting for baseline differences and, if found, to
investigate its effect on the composite of death or nonfatal
reinfarction at 30 days. Variables included in this model were
age, gender, race, smoking status, hyperlipidemia, hyperten-
sion, diabetes, peripheral vascular disease, family history of
coronary artery disease, site of enrollment (inside or outside
the United States), cardiac history, recent history of malig-
nancy, height, weight, systolic and diastolic blood pressures,
heart rate and Killip class (Table 1). Because this model was
developed to adjust for baseline imbalances between the t-PA
and SK groups, it also allowed us to compare t-PA and SK
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
aPTT 5 activated partial thromboplastin time
CI 5 confidence interval
df 5 degrees of freedom
GUSTO 5 Global Use of Strategies to Open Occluded Coronary
Arteries in Acute Coronary Syndromes
MI 5 myocardial infarction
OR 5 odds ratio
SK 5 streptokinase
TIMI 5 Thrombolysis in Myocardial Infarction
t-PA 5 tissue-type plasminogen activator
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(with either hirudin or heparin) with regard to the composite
end point.
Results
Patient treatment groups. Of the 2,274 patients treated
with t-PA, 1,919 received t-PA rather than SK at the discretion
of their physicians, and another 355 patients were randomized
to receive t-PA as part of the direct angioplasty substudy. Of
these 2,274 patients, 1,151 had been randomized to receive
hirudin and 1,123 to receive heparin. Of the 1,015 patients
treated with SK, 500 had been randomized to receive hirudin
and 515 to receive heparin.
Within either thrombolytic group, patients assigned to
receive heparin and those assigned to receive hirudin did not
differ significantly at baseline (Table 1). However, patients
treated with t-PA were younger and more often male, smokers
or hypercholesterolemic than those treated with SK. Patients
treated with t-PA also had more previous angina, and their
Killip classification was less severe.
Within the SK group, hirudin treatment was associated with
a 34% relative reduction in 30-day mortality compared with
heparin treatment (p 5 0.092) (Fig. 1). There was also a
relative reduction of 50% (p 5 0.007) in the rate of reinfarc-
tion at 30 days with hirudin and a relative reduction of 40% in
the incidence of the composite 30-day end point of death or
nonfatal reinfarction (p 5 0.004). Within the t-PA group,
treatment groups did not differ significantly at 30 days with
regard to rates of death, nonfatal reinfarction or the two
combined. The test for an interaction between the thrombo-
lytic and antithrombin agents yielded an unadjusted chi-square
value of 4.20 (degrees of freedom [df] 1, p 5 0.04); that is, the
treatment effect of hirudin was statistically different for the SK
and t-PA groups.
At 24 h, patients fared better if they had received SK and
hirudin than heparin (Fig. 2). There was a 49% relative
reduction in mortality with hirudin (p 5 0.093). Hirudin was
also associated with an 89% relative reduction in the incidence
of reinfarction (p 5 0.013), but there were very few events.
Similarly, hirudin was associated with a relative reduction of
61% (p 5 0.009) in the incidence of the composite end point
of death or nonfatal reinfarction at 24 h. Within the t-PA
group, patients treated with heparin or hirudin did not differ
significantly with regard to the 24-h end points.
Moderate bleeding occurred more often with t-PA than
with SK treatment and least often in patients who received
SK and heparin (Table 2). However, patients treated with SK
with heparin were the most likely, and those treated with
SK with hirudin were the least likely, to have severe bleeding.
With either antithrombin agent, SK yielded a lower rate for the
combination of moderate or severe bleeding than did t-PA. In
the SK group, fewer hemorrhagic strokes were seen in patients
Figure 1. Odds ratios and 95% confidence intervals for the unadjusted
risk of death, reinfarction or death or reinfarction at 30 days with
hirudin versus heparin treatment with SK (top) or accelerated t-PA
(bottom).
Table 1. Baseline Characteristics of Patients With ST Segment
Elevation Myocardial Infarction According to Thrombolytic and
Antithrombin Therapy
t-PA Streptokinase
Hirudin
(n 5 1,151)
Heparin
(n 5 1,123)
Hirudin
(n 5 500)
Heparin
(n 5 515)
Median age (yr) 61 62 65 64
Male gender 79% 79% 76% 73%
White 94% 95% 97% 96%
Current smoker 43% 43% 39% 41%
Hypercholesterolemia 38% 39% 32% 34%
Hypertension 39% 40% 34% 38%
Diabetes 14% 17% 13% 17%
PVD 6% 7% 8% 7%
Family history of
CAD
40% 38% 37% 36%
U.S. enrollment 44% 44% 10% 11%
Previous MI 16% 17% 16% 17%
Previous angina 48% 48% 43% 45%
Previous CABG 5% 5% 4% 5%
Previous CHF 2% 2% 2% 3%
Previous CVD 2% 2% 2% 1%
Cancer diagnosed or
treated within last
5 yr
3% 2% 3% 3%
Mean SBP (mm Hg) 130 130 130 130
Mean DBP
(mm Hg)
80 80 80 80
Mean HR
(beats/min)
74 74 72 73
Mean height (cm) 171 171 170 170
Mean weight (kg) 79 80 77 77
Killip class
I 90% 88% 87% 84%
II 9% 11% 11% 14%
III 1% 0.9% 1% 2%
IV 0.4% 0.4% 0.4% 0.2%
Data presented are percent of patients, unless otherwise indicated. CABG 5
coronary artery bypass graft surgery; CAD 5 coronary artery disease; CHF 5
congestive heart failure; CVD 5 cerebrovascular disease; DBP 5 diastolic blood
pressure; HR 5 heart rate; MI 5 myocardial infarction; PVD 5 peripheral
vascular disease; SBP 5 systolic blood pressure; t-PA 5 tissue-type plasminogen
activator.
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treated with heparin than in those given hirudin (although
event rates were very low). Differences among the four groups
in bleeding complications were not statistically significant, nor
were differences in bleeding outcomes by antithrombin agent
within each thrombolytic group.
At 6 h after thrombolytic therapy began, within each
thrombolytic group the median aPTT was significantly longer
for those treated with heparin than for those treated with
hirudin (Fig. 3). However, within each thrombolytic group the
median values at 12 and 24 h were shorter for those treated
with heparin than with hirudin. Over the first 24 h, aPTT values
varied less overall in patients treated with hirudin. For hirudin,
there was considerably less variability from the 25th and 75th
percentiles at 6, 12 and 24 h, as shown in Figure 3. Ninety-four
percent of patients in this substudy did have an MI by cardiac
enzyme levels. All patients classified as having reinfarction did
have an MI by measurement of enzyme levels on presentation.
Among patients treated with SK, cardiogenic shock oc-
curred less often with hirudin than with heparin treatment
(4.8% vs. 7.2%, p 5 0.11) (Table 3). Similarly, recurrent
ischemia occurred less often in patients treated with hirudin
(21.2% vs. 25.4%, p 5 0.11), as did refractory ischemia (7.2%
vs. 10.9%, p 5 0.04). However, stroke occurred more often in
patients treated with hirudin (1.6% vs. 0.6%, p 5 0.12). Among
patients receiving t-PA, there were no significant differences
between treatment groups with regard to any of these out-
comes. The incidence of congestive heart failure did not differ
by antithrombin agent within the thrombolytic groups.
Analysis. A multivariable regression model was applied to
adjust for known imbalances in baseline characteristics be-
tween the t-PA and SK groups. After adjustment, the risk of
the composite 30-day end point of death or nonfatal reinfarc-
tion was similar in three groups: patients treated with SK and
hirudin (9.1%), those treated with t-PA and hirudin (10.3%)
and those treated with t-PA and heparin (10.5%). However,
the risk was significantly lower in patients treated with SK and
hirudin than with SK and heparin (9.1% vs. 14.9%, odds ratio
[OR] 0.57, 95% confidence interval [CI] 0.38 to 0.87, p 5
0.009, a relative reduction of 39%). The adjusted 30-day rate of
death or nonfatal reinfarction for t-PA and hirudin treatment
(10.3%) was similar to that for t-PA and heparin treatment
(10.5%, p 5 0.91, OR 0.98, 95% CI 0.74 to 1.30). The
Figure 2. Odds ratios and 95% confidence intervals for the unadjusted
risk of death, reinfarction or death or reinfarction at 24 h with hirudin
versus heparin treatment with SK (top) or accelerated t-PA (bottom).
Figure 3. aPTT time at 6, 12 and 24 h after enrollment in patients who
received (from left to right) t-PA and hirudin; t-PA and heparin; SK
and hirudin; or SK and heparin. Box plots: top horizontal lines 5 75th
percentiles; intermediate horizontal lines 5 medians; bottom lines 5
25th percentiles; vertical lines above and below boxes 5 95% confi-
dence interval.
Table 2. In-Hospital Bleeding Complications of Patients With ST
Segment Elevation Myocardial Infarction According to
Thrombolytic and Antithrombin Therapy*
t-PA Streptokinase
Hirudin
(n 5 1,151)
Heparin
(n 5 1,123)
Hirudin
(n 5 500)
Heparin
(n 5 515)
Moderate bleeding 9.0% 9.1% 7.6% 6.2%
Severe bleeding 1.4% 0.8% 0.6% 1.6%
Moderate or severe
bleeding
10.3% 9.7% 8.0% 7.6%
Hemorrhagic
stroke
0.7% 0.7% 0.6% 0.2%
*p 5 NS for all comparisons. Data presented are percent of patients. t-PA 5
tissue-type plasminogen activator.
Table 3. Clinical Outcomes at 30 Days in Patients With ST Segment
Elevation Myocardial Infarction According to Thrombolytic and
Antithrombin Therapy*
t-PA Streptokinase
Hirudin
(n 5 1,151)
Heparin
(n 5 1,123)
Hirudin
(n 5 500)
Heparin
(n 5 515)
Cardiogenic shock 4.9% 5.0% 4.8% 7.2%
Stroke 1.4% 1.3% 1.6% 0.6%
CHF 9.4% 8.7% 10.1% 9.3%
Recurrent ischemia 24.1% 24.3% 21.2% 25.4%
Refractory
ischemia
8.7% 8.9% 7.2% 10.9%
*Data not complete for European patients; the denominators for this
outcome are 628, 608, 198 and 225 for tissue-type plasminogen activator
(t-PA)– hirudin, t-PA– heparin, streptokinase– hirudin and streptokinase–
heparin, respectively. Data presented are percent of patients. CHF 5 congestive
heart failure.
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interaction between antithrombin treatment and thrombolytic
agent was significant (chi-square 4.5, df 1, p 5 0.03).
Discussion
Subgroup analysis. The present subgroup analysis of pa-
tients treated with thrombolytic therapy for acute myocardial
infarction (AMI) in the GUSTO-IIb trial reveals a beneficial
effect of hirudin with SK but not t-PA. As an adjunct to SK,
hirudin resulted in a lower combined incidence of death and
nonfatal reinfarction than did heparin, both at 24 h and at 30
days. However, as an adjunct to t-PA hirudin did not differ
significantly from heparin in its effects on these composite end
points. The interaction between the antithrombin and throm-
bolytic agents with regard to the prevention of death and
reinfarction at 30 days remained significant after adjustment
for independent variables. The combination of SK and hirudin
had the lowest adjusted 30-day rate of the composite end point
of the four strategies (9.1%, an absolute reduction of 5.8%
from the 14.9% rate with SK and heparin treatment).
Previous studies. Although potential mechanisms for im-
proved outcomes with hirudin as an adjunct to SK remain
uncertain, the results of an angiographic infarct-related vessel
patency trial with another direct thrombin inhibitor, hirulog
(the Hirulog Early Reperfusion Occlusion [HERO] trial [6])
showed a significant increase in early (90 min) infarct-related
vessel patency with hirulog compared with heparin among
patients treated with SK. These data were corroborated by
another patency trial of hirulog in patients with an AMI (7). In
fact, the patency rates in both trials for SK with hirulog
approximated that seen with accelerated t-PA with heparin in
the GUSTO-I angiographic substudy (12). Two other random-
ized trials of SK and hirudin also have shown favorable results
for this combination with respect to early infarct-related vessel
patency (5) and clinical end points (4).
An angiographic substudy was not included in the GUSTO-
IIb trial, but the aforementioned trials suggest that improved
early infarct-related vessel patency is the likely mechanism for
improved outcomes in the patients treated with SK and
hirudin. Additionally, the reduced rates of refractory ischemia,
recurrent ischemia and cardiogenic shock in patients so
treated, consistent with the reduced rate of the composite end
point of death or nonfatal reinfarction, suggest improved blood
flow in the infarct-related artery. Although the incidence of
bleeding complications did not differ significantly between
hirudin and heparin, the slightly greater incidence of intracra-
nial hemorrhage with hirudin (0.6% SK/hirudin vs. 0.2%
SK/heparin) is noteworthy and is consistent with more exten-
sive clot lysis. This hemorrhage rate is similar to that with t-PA
(0.7% for both hirudin and heparin) and improved when
compared with the results of previous trials that used higher
doses of antithrombin agents (13–15).
Thrombolytic therapy induces both thrombin generation
(measured by prothrombin fragment 1.2) and thrombin activity
(measured by fibrinopeptide A). A laboratory study by Brom-
mer and Meijer (16) has shown that SK accelerates thrombin
generation more than t-PA, and thrombin generation was
completely halted by the addition of hirudin to SK in the test
medium. A substudy of 293 patients in the GUSTO-I trial (17)
showed a greater increase in thrombin–antithrombin com-
plexes after SK than t-PA, consistent with the hypothesis that
SK exposes more thrombin than t-PA. These data, which show
greater amounts and activity levels of thrombin after SK than
t-PA, provide a pathophysiologic rationale for our findings.
Of five previous studies of SK and direct thrombin inhibi-
tion (4–7,18), only one did not show improvement in rates of
death and reinfarction with direct thrombin inhibitors. In that
trial, the Thrombolysis and Thrombin Inhibition in Myocardial
Infarction (TIMI-9B) study (18), 1,496 patients were randomly
assigned to receive heparin and 1,506 hirudin, at dosages
similar to those used in GUSTO-IIb. These patients also
received either t-PA or SK at the discretion of their physicians.
The incidence of the composite end point of death or nonfatal
reinfarction did not differ significantly by thrombolytic or
antithrombin agent. Analysis of the timing of study drug
administration after thrombolysis suggests a reason for the
significant benefits observed in GUSTO-IIb but not in TIMI-
9B. The study drug was given a mean of 35 min after
thrombolysis in GUSTO-IIb, and systemic thrombin activity
has been shown (19) to peak 30 min after administration of SK
in patients with an AMI. The median time from randomization
to institution of study drug was 44 min in TIMI-9B, possibly
explaining why the additive benefit of hirudin with SK was not
observed in that study. The patients in TIMI-9B who were
treated with hirudin rather than heparin within 30 min of
randomization did show a strong trend toward a lower rate of
death or reinfarction than patients treated with either drug
after 30 min (20). This finding emphasizes that early treatment
with hirudin or hirulog may be important to obtain maximal
benefit from these potent thrombin inhibitors (21).
The direct thrombin inhibitors are the first antithrombin
agents to improve the outcomes of patients treated with SK.
Delayed subcutaneous heparin did not improve survival when
used with either conventional t-PA or SK in the combined data
from the Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico (GISSI-2) and the Third International
Study of Infarct Survival (ISIS-3) trials, which together in-
cluded 62,000 patients treated for AMI. With the addition of
subcutaneous heparin, there was no significant survival benefit
at 30 to 35 days, and there was an excess incidence of major
bleeding, including an excess of about one cerebral hemor-
rhage per 1,000 patients treated (22–25). Similarly in the
GUSTO-I trial, no incremental benefit was shown for intrave-
nous than for subcutaneous heparin with SK; the mortality rate
in both groups was nearly identical at 30 days (2). Thus, the
role for intravenous heparin as an adjunct to SK in AMI
remains controversial (26). Although a recent meta-analysis
(27,28) of 26 randomized trials of anticoagulant therapy versus
control in suspected AMI has questioned the need to add
heparin to a regimen of aspirin and any thrombolytic agent,
including t-PA, published guidelines (29) continue to recom-
mend that heparin be used an adjunct to t-PA.
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Study limitations. The limitations of the present study
relate to the use of a subgroup of patients for analysis (27.1%
of the total enrollment of GUSTO-IIb), even though the
subgroup was specified in advance. The GUSTO-IIb trial was
powered to detect a significant difference between the hirudin
and heparin groups for the entire patient population, including
those with and without ST segment elevation MI. Because
patients were not randomized to receive t-PA or SK, com-
parisons between these thrombolytic agents must adjust for
differences in baseline characteristics. Although we used a
multivariate logistic regression model to perform such adjust-
ments, the comparison of the thrombolytic agents should be
regarded as exploratory.
Conclusions. The results of the present analysis support
the combination of the direct thrombin inhibitor hirudin and
SK as a promising alternative to the current standard therapy
of t-PA with heparin. The more potent, direct thrombin
inhibitors may improve clinical outcomes with SK, a less
effective agent than t-PA when used with intravenous heparin
(2). There may also be significant cost savings with SK and
hirudin because t-PA currently costs ;$1,800 more per treat-
ment than SK. Further large, randomized trials are needed to
confirm the benefits of using direct thrombin inhibitors with
SK in acute ST segment elevation MI. Nevertheless, our
findings confirm the importance of thrombin activity in pa-
tients receiving SK therapy.
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